Posted by Michael Wonder on 19 Mar 2018
Funding breakthrough therapies: a systematic review and recommendation
17 March 2018 - Advanced therapy medicinal products are innovative therapies likely associated with high prices.
Payers need guidance to create a balance between ensuring patient access to breakthrough therapies and maintaining the financial sustainability of the health care system.
The aims of this study were to identify, define, classify and compare the approaches to funding high-cost medicines proposed in the literature, to analyse their appropriateness for advanced therapy medicinal products (ATMPs) funding and to suggest an optimal funding model for ATMPs.
